Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1960 1
1962 6
1964 3
1965 4
1966 3
1967 6
1968 5
1969 10
1970 14
1971 10
1972 4
1973 14
1974 6
1975 10
1976 7
1977 9
1978 9
1979 7
1980 6
1981 9
1982 11
1983 4
1984 6
1985 10
1986 10
1987 14
1988 7
1989 9
1990 11
1991 9
1992 13
1993 5
1994 8
1995 4
1996 8
1997 10
1998 9
1999 10
2000 15
2001 18
2002 11
2003 21
2004 16
2005 18
2006 31
2007 26
2008 26
2009 26
2010 19
2011 27
2012 37
2013 44
2014 38
2015 54
2016 59
2017 56
2018 71
2019 81
2020 85
2021 77
Text availability
Article attribute
Article type
Publication date

Search Results

1,067 results
Results by year
Filters applied: . Clear all
Page 1
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Among authors: hong rl. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Proteogenomic Characterization Reveals Therapeutic Vulnerabilities in Lung Adenocarcinoma.
Gillette MA, Satpathy S, Cao S, Dhanasekaran SM, Vasaikar SV, Krug K, Petralia F, Li Y, Liang WW, Reva B, Krek A, Ji J, Song X, Liu W, Hong R, Yao L, Blumenberg L, Savage SR, Wendl MC, Wen B, Li K, Tang LC, MacMullan MA, Avanessian SC, Kane MH, Newton CJ, Cornwell M, Kothadia RB, Ma W, Yoo S, Mannan R, Vats P, Kumar-Sinha C, Kawaler EA, Omelchenko T, Colaprico A, Geffen Y, Maruvka YE, da Veiga Leprevost F, Wiznerowicz M, Gümüş ZH, Veluswamy RR, Hostetter G, Heiman DI, Wyczalkowski MA, Hiltke T, Mesri M, Kinsinger CR, Boja ES, Omenn GS, Chinnaiyan AM, Rodriguez H, Li QK, Jewell SD, Thiagarajan M, Getz G, Zhang B, Fenyö D, Ruggles KV, Cieslik MP, Robles AI, Clauser KR, Govindan R, Wang P, Nesvizhskii AI, Ding L, Mani DR, Carr SA; Clinical Proteomic Tumor Analysis Consortium. Gillette MA, et al. Among authors: hong r. Cell. 2020 Jul 9;182(1):200-225.e35. doi: 10.1016/j.cell.2020.06.013. Cell. 2020. PMID: 32649874 Free PMC article.
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.
Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Chen QJ, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Su YH, Hua X, Wang XY, Hong RX, Jiang KK, Song CG, Huang ZZ, Shi W, Zhong YY, Yuan ZY; South China Breast Cancer Group (SCBCG). Wang X, et al. Among authors: hong rx. JAMA. 2021 Jan 5;325(1):50-58. doi: 10.1001/jama.2020.23370. JAMA. 2021. PMID: 33300950 Free PMC article. Clinical Trial.
Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer.
Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR. Kishan AU, et al. Among authors: hong rl. JAMA Netw Open. 2019 Feb 1;2(2):e188006. doi: 10.1001/jamanetworkopen.2018.8006. JAMA Netw Open. 2019. PMID: 30735235 Free PMC article.
A High-Throughput Immune-Oncology Screen Identifies EGFR Inhibitors as Potent Enhancers of Antigen-Specific Cytotoxic T-lymphocyte Tumor Cell Killing.
Lizotte PH, Hong RL, Luster TA, Cavanaugh ME, Taus LJ, Wang S, Dhaneshwar A, Mayman N, Yang A, Kulkarni M, Badalucco L, Fitzpatrick E, Kao HF, Kuraguchi M, Bittinger M, Kirschmeier PT, Gray NS, Barbie DA, Jänne PA. Lizotte PH, et al. Among authors: hong rl. Cancer Immunol Res. 2018 Dec;6(12):1511-1523. doi: 10.1158/2326-6066.CIR-18-0193. Epub 2018 Sep 21. Cancer Immunol Res. 2018. PMID: 30242021 Free PMC article.
Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141).
Yen CJ, Kiyota N, Hanai N, Takahashi S, Yokota T, Iwae S, Shimizu Y, Hong RL, Goto M, Kang JH, Li WSK, Ferris RL, Gillison M, Endo T, Jayaprakash V, Tahara M. Yen CJ, et al. Among authors: hong rl. Head Neck. 2020 Oct;42(10):2852-2862. doi: 10.1002/hed.26331. Epub 2020 Jun 24. Head Neck. 2020. PMID: 32583557 Free PMC article. Clinical Trial.
Corrigendum.
Koneru SL, Salinas H, Flores GE, Hong RL. Koneru SL, et al. Among authors: hong rl. Mol Ecol. 2016 Dec;25(24):6267. doi: 10.1111/mec.13924. Mol Ecol. 2016. PMID: 28035759 No abstract available.
1,067 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page